Valuation: Sernova Biotherapeutics Inc

Market Cap 41.54M 29.93M 25.85M 24.3M 22.1M 2.86B 42.23M 285M 111M 1.43B 112M 110M 4.76B P/E 2026 *
-3.67x
P/E 2027 * -2.75x
Enterprise Value 41.54M 29.93M 25.85M 24.3M 22.1M 2.86B 42.23M 285M 111M 1.43B 112M 110M 4.76B EV / Sales 2026 *
-
EV / Sales 2027 * 8.31x
Free-Float
86.84%
Yield 2026 *
-
Yield 2027 * -
1 week-4.35%
3 months-29.03%
6 months-24.14%
Current year-15.38%
1 week 0.1
Extreme 0.105
0.12
1 month 0.1
Extreme 0.105
0.12
Current year 0.1
Extreme 0.105
0.2
1 year 0.1
Extreme 0.105
0.2
3 years 0.1
Extreme 0.105
0.91
5 years 0.1
Extreme 0.105
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 11/08/2024
Director of Finance/CFO 60 10/10/2024
Investor Relations Contact - 10/10/2024
Director TitleAgeSince
Director/Board Member 60 18/04/2012
Director/Board Member - 23/04/2023
Director/Board Member - 31/08/2024
Date Insider Type Main position Quantity % Market Cap.
03/07/26 SellCompany -115,000 0.0305%
22/05/26 Option

Director

173,418 0.0499%
27/02/26 Option

Director

377,970 0.1123%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.35%-45.00%-86.59% 29.93M
-0.55%+0.05%-11.18%+20.45% 130B
-0.86%-1.53%-18.54%+2.14% 12.49B
-2.60%+2.51%+105.35%+148.76% 10.88B
-2.43%-4.22%-44.57%-67.28% 4.51B
-0.88%+0.67%-24.25%+42.34% 2.72B
-1.32%-1.42%-21.31%-13.79% 1.66B
-0.17%-0.04%-33.47%-35.74% 1.66B
-1.89%-5.09%-34.94%-75.32% 1.65B
Average -1.19%-1.13%-14.21%-7.23% 18.41B
Weighted average by Cap. -0.78%-0.09%-5.78%+23.59%

Financials

2026 *2027 *
Net sales - 5M 3.6M 3.11M 2.92M 2.66M 345M 5.08M 34.26M 13.4M 173M 13.53M 13.23M 573M
Net income -12.83M -9.24M -7.98M -7.5M -6.82M -884M -13.04M -87.9M -34.37M -443M -34.7M -33.95M -1.47B -19.77M -14.25M -12.31M -11.56M -10.52M -1.36B -20.1M -135M -52.98M -682M -53.49M -52.33M -2.27B
Net Debt - -
Logo Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
8
Date Price Change Volume
14/08/26 CA$0.1100 0.00% 5,147
13/08/26 CA$0.1100 -4.35% 105,181
12/08/26 CA$0.1150 +4.55% 134,600
11/08/26 CA$0.1100 0.00% 11,645
10/08/26 CA$0.1100 -4.35% 106,500
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1100CAD
Average target price
0.4500CAD
Spread / Average Target
+309.09%

Quarterly revenue - Rate of surprise